Google
Top Midday Gainers
Replimune (REPL) stock soared 94% after the company late Thursday reported a favorable outcome of the US Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in advanced melanoma.The committee voted 10 to 3 that the efficacy
Silver
Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now
